The Ophthalmic Innovation Program at the Byers Eye Institute at Stanford

The Program

Daniel Palanker, PhD and Mark Blumenkranz MD co-invented the PASCAL patterned scanning laser that is now considered the standard of care in the treatment of diabetic retinopathy and has been used to treat millions of patients worldwide. Retina photo courtesy of Daniel Lavinsky, MD

The Stanford Ophthalmic Innovation Program offers an immersive, year-long didactic and project-based fellowship in the conceptualization and implementation of technology and processes to improve eye care. This includes the sequential stages of development that are necessary for successful commercialization and adoption into patient care paradigms. The curriculum will blend the following four components: hands-on projects, formal coursework, close mentorship, and networking and internship opportunities with members of the Department of Ophthalmology, other Stanford departments, Silicon Valley innovators, and colleagues at the FDA.

Stanford University and the Department of Ophthalmology have existing collaborative educational and research programs in place with the Center for Devices and Radiological Health (CDRH) at the Food and Drug Administration (FDA) in the area of regulatory science. Fellows will have the opportunity to participate in projects within these programs during the course of the year.

The Stanford Ophthalmic Innovation Program is affiliated with the Stanford Byers Center for Biodesign. Fellows of the Ophthalmic Innovation Program will have the opportunity to apply for the two-quarter Biodesign Innovation Course (BioE 274A/B) and participate in selected other Stanford educational programs in these basic areas offered by the university. For more information about Biodesign, please visit

A Tradition of Successful Innovation

David Myung, MD, PhD and Robert Chang, MD co-invented Paxos Scope™, the first combined anterior and posterior ophthalmic camera system for smartphones. Seed funded through a grant from the Stanford Biodesign Program and licensed to Digisight Technologies, Paxos Scope was registered with the FDA as a 510k Class II exempt ophthalmic camera in 2015.

Clinician scientists and basic researchers at the Byers Eye Institute at Stanford have a rich tradition in ophthalmic innovation. Over the past several decades Stanford Ophthalmology faculty have led the way toward a number of ground breaking discoveries and technologies, many of which have been out-licensed through the Stanford Office of Technology Licensing and served as the foundation for the establishment of innovative Silicon Valley companies that translated them into practice-altering commercial products. These technologies are in various stages of evolution ranging from pre-clinical studies to full FDA approval, and have provided the roots for a number of free-standing, venture-backed companies, including Optimedica (which developed the PASCAL and Catalys laser and was acquired by AMO), PEAK Surgical(plasma-mediated surgical tools, acquired by Medtronic), Oculeve (neurostimulation devices for dry eye, acquired by Allergan), Adverum Biotechnologies (gene therapy, NASDAQ:ADVM), Pixium (artificial retinal prosthesis) and DigiSight Technologies (mobile health). Millions of patients worldwide have been impacted by technologies developed by inventors from Stanford Ophthalmology.



Applications are now open and due no later than June 30, 2018 to be considered for the 2019-2020 academic year program.

Please prepare a CV and 1-page personal statement that includes goals for the year and career following the fellowship, and/or any questions via email to the Ophthalmic Innovation Program Fellowship, c/o Sylvie Pham:

Candidate Selection Criteria

It is expected that fellows have an MD and/or PhD Degree with a minimum of two or more years of post-graduate training or work experience in one of several disciplines including Ophthalmology, Vision Science Research, Bioengineering, Computer Science, or Business. The timeframe of the fellowship is intended to be 12 months.

Candidates with one or more of the following will be given strong consideration:

  • Ophthalmology residency or fellowship (encouraged but not required)
  • PhD in areas with relevance to vision science (neuroscience, molecular/cellular biology, biophysics, biochemistry, chemistry, engineering, computer science, or related disciplines)
  • MBA and/or industry experience
  • Other significant experience in ophthalmic (or related) research and innovation in industry or academic institutions
  • We expect that all will have a passion for and some existing ideas about transforming eye care

2018-2019 Ophthalmic Innovation Fellow

Frank Brodie, MD, MBA 

Dr. Brodie recently completed his Ophthalmology residency at University of California San Francisco. Prior to that, he was at Harbor UCLA for an internal medicine internship. He completed his MD and MBA at University of Pennsylvania School of Medicine and The Wharton School respectively. In his free time, Frank enjoys exploring the Bay Area with his wife Rachel, an OB/GYN at Kaiser, and their dog Harley, a 1-year-old Golden Retriever.

2017-2018 FELLOW

Alexander Kreymerman

Alexander Kreymerman received his BS in biological sciences, an MS in molecular biology, and is a University of Miami and Stanford affiliated PhD candidate in neurosciences with a focus on retinal regeneration and neuroprotection. He has had affiliations with 5 research institutes with strong ophthalmology and translational research focuses, through his MS and PhD training; including collaborations with the Scripps Research Institute, Max Plank, Center for Molecular biology and Biotechnology at FAU, Bascom Palmer, Shiley Eye Institute UCSD, and currently in the Stanford Ophthalmology Departments. Alex has also held positions at a NASA affiliated imaging technology development center, a cancer and neuroprotection drug development and screening start up, and in the molecular biology/neuroscience research departments at FAU-Scripps-Max Plank campuses. His major research projects and professional interests are focused on the development of novel, high resolution, and minimally invasive intraoperative imaging and microscopy devices as well as gene therapy and drug development for ocular pathologies. As the Innovation Fellow in the ophthalmology department, Alex is continuing to develop technologies that focus on gene therapy for retinal dystrophies and intraoperative imaging for retinal and orbital surgery. In his spare time, he enjoys spearfishing, freediving, mountaineering, and travel. 

2016-2017 FELLOW

Zachary Bodnar, MD

Dr. Bodnar was born and raised in Salt Lake City, Utah. He attended the Massachusetts Institute of Technology, where he earned a BS in electrical engineering and computer science, followed by a masters of engineering, also in electrical engineering and computer science. He worked for the enterprise software startup Endeca for several years, prior to its acquisition by Oracle, until he matriculated in Dartmouth Medical School where he earned his MD. Dr. Bodnar completed the Ophthalmic Pathology and Research fellowship at the John A. Moran Eye Center, at the University of Utah, internship in general surgery at the Mayo Clinic Hospital in Phoenix and residency in ophthalmology at Saint Louis University. His academic interests include machine vision, machine learning, digital signal processing and their applications to ophthalmic imaging and medical informatics. In his spare time Dr. Bodnar enjoys snowboarding, backpacking and photography.


Mark Blumenkranz, MD

David Myung, MD, PhD

Darius Moshfeghi, MD

Daniel Palanker, PhD

Robert Chang, MD

Jeffrey Goldberg, MD, PhD